DE69915486D1 - Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne - Google Patents

Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne

Info

Publication number
DE69915486D1
DE69915486D1 DE69915486T DE69915486T DE69915486D1 DE 69915486 D1 DE69915486 D1 DE 69915486D1 DE 69915486 T DE69915486 T DE 69915486T DE 69915486 T DE69915486 T DE 69915486T DE 69915486 D1 DE69915486 D1 DE 69915486D1
Authority
DE
Germany
Prior art keywords
eletriptan
migraine
recurrence
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69915486T
Other languages
English (en)
Other versions
DE69915486T2 (de
Inventor
Colin Jackson
Stephen Uden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69915486D1 publication Critical patent/DE69915486D1/de
Publication of DE69915486T2 publication Critical patent/DE69915486T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69915486T 1998-07-30 1999-06-14 Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne Expired - Fee Related DE69915486T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9816556 1998-07-30
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy
PCT/IB1999/001105 WO2000006161A1 (en) 1998-07-30 1999-06-14 Prevention of migraine recurrence

Publications (2)

Publication Number Publication Date
DE69915486D1 true DE69915486D1 (de) 2004-04-15
DE69915486T2 DE69915486T2 (de) 2005-03-03

Family

ID=10836395

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69915486T Expired - Fee Related DE69915486T2 (de) 1998-07-30 1999-06-14 Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne

Country Status (36)

Country Link
EP (3) EP1100499B1 (de)
JP (1) JP3824863B2 (de)
KR (2) KR100441732B1 (de)
CN (2) CN1522697A (de)
AP (1) AP1402A (de)
AT (1) ATE261304T1 (de)
AU (1) AU3952199A (de)
BG (1) BG65309B1 (de)
BR (1) BR9912588A (de)
CA (1) CA2338901C (de)
CZ (1) CZ2001357A3 (de)
DE (1) DE69915486T2 (de)
DK (1) DK1100499T3 (de)
EA (2) EA004036B1 (de)
EE (1) EE04703B1 (de)
ES (1) ES2214027T3 (de)
GB (1) GB9816556D0 (de)
GE (2) GEP20063719B (de)
HK (1) HK1038198A1 (de)
HR (1) HRP20010079A2 (de)
HU (1) HUP0103424A3 (de)
ID (1) ID26996A (de)
IL (1) IL140169A0 (de)
IS (1) IS2253B (de)
NO (1) NO20010489L (de)
NZ (2) NZ508736A (de)
OA (1) OA11576A (de)
PL (1) PL194611B1 (de)
PT (1) PT1100499E (de)
SG (1) SG125910A1 (de)
SK (1) SK1182001A3 (de)
TR (1) TR200100314T2 (de)
TW (2) TW537893B (de)
UA (1) UA76399C2 (de)
WO (1) WO2000006161A1 (de)
YU (2) YU6401A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
US7332183B2 (en) 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
WO2009152551A1 (en) 2008-06-20 2009-12-23 Alphapharm Pty Ltd Pharmaceutical formulation
EP2490669B1 (de) * 2009-10-23 2017-01-11 Fortuderm Ltd. Triptane zur behandlung von schuppenflechte
RU2670272C2 (ru) * 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
IL127956A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US6166025A (en) * 1997-07-03 2000-12-26 Pfizer Inc. Pharmaceutical compositions containing eletriptran hemisulphate and caffeine
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Also Published As

Publication number Publication date
AU3952199A (en) 2000-02-21
UA76399C2 (en) 2006-08-15
CA2338901A1 (en) 2000-02-10
SG125910A1 (en) 2006-10-30
EE04703B1 (et) 2006-10-16
HUP0103424A2 (hu) 2002-02-28
KR100441732B1 (ko) 2004-07-27
TW200300674A (en) 2003-06-16
TWI248362B (en) 2006-02-01
BG65309B1 (bg) 2008-01-31
PT1100499E (pt) 2004-06-30
IS5771A (is) 2000-12-15
CN1155379C (zh) 2004-06-30
ES2214027T3 (es) 2004-09-01
OA11576A (en) 2004-07-01
EP1100499B1 (de) 2004-03-10
IS2253B (is) 2007-06-15
EA200100089A1 (ru) 2001-08-27
CN1522697A (zh) 2004-08-25
EE200100061A (et) 2002-06-17
CN1309560A (zh) 2001-08-22
YU6401A (sh) 2004-03-12
EP1466601A2 (de) 2004-10-13
EP1435237A1 (de) 2004-07-07
NO20010489D0 (no) 2001-01-29
HRP20010079A2 (en) 2002-02-28
ID26996A (id) 2001-02-22
IL140169A0 (en) 2002-02-10
BR9912588A (pt) 2001-05-02
AP1402A (en) 2005-04-29
EA200201149A1 (ru) 2003-02-27
JP2002521446A (ja) 2002-07-16
EP1466601A3 (de) 2005-04-13
CZ2001357A3 (cs) 2001-10-17
HK1038198A1 (en) 2002-03-08
CA2338901C (en) 2008-02-19
TW537893B (en) 2003-06-21
GB9816556D0 (en) 1998-09-30
KR20030078876A (ko) 2003-10-08
GEP20063719B (en) 2006-01-10
GEP20043157B (en) 2004-01-26
WO2000006161A1 (en) 2000-02-10
DE69915486T2 (de) 2005-03-03
BG105277A (en) 2001-11-30
NO20010489L (no) 2001-03-26
EA004036B1 (ru) 2003-12-25
DK1100499T3 (da) 2004-06-14
NZ508736A (en) 2003-09-26
PL345803A1 (en) 2002-01-02
TR200100314T2 (tr) 2001-06-21
JP3824863B2 (ja) 2006-09-20
EP1100499A1 (de) 2001-05-23
HUP0103424A3 (en) 2003-05-28
YU20303A (sh) 2006-08-17
NZ527625A (en) 2005-01-28
SK1182001A3 (en) 2001-10-08
KR20010079582A (ko) 2001-08-22
AP2001002056A0 (en) 2001-03-31
ATE261304T1 (de) 2004-03-15
PL194611B1 (pl) 2007-06-29

Similar Documents

Publication Publication Date Title
DE69932032D1 (de) Inhibitoren der alpha4 vermittelten zelladhäsion
DE69813616D1 (de) Cyclohexencarboxylate als inhibitoren der neuraminidase
PL342243A1 (en) Substituted oxoazaheterocyclic inhibitors of the factor xa
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69732881D1 (de) Verwendung von zusammensetzungen mit stabilisierten enzymen
DE60037213D1 (de) Verwendung von Reinigungsgas
DE69915486D1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
DE69838042D1 (de) Verwendung von Inhibitoren des Renin-Angiotensin Systems
ATE240318T1 (de) Substituierte bisindolylmaleimide zur inhibierung der zellproliferation
ATE224889T1 (de) Substituierte bisindolylmaleimide zur inhibierung der zellproliferation
ATE243693T1 (de) Substituierte bisindolylmaleimide zur inhibierung der zellproliferation
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69924488D1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
ATE347551T1 (de) Substituierte bisindolylmaleimide zur inhibierung der zellproliferation
ATE303153T1 (de) Ibandroinsäure zur förderung der osseointegration der endoprothesen
ATE270545T1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
ID29101A (id) Komposisi yang mengandung bitumen dalam bentuk butiran
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
KR980003137U (ko) 퇴수를 재공급 사용토록 한 개량부동전
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose
DE69840980D1 (de) Verwendung des mutierten hitzeschock-transkriptionfaktors
DE59908293D1 (de) Polymermischungen zur Verbesserung der Schmierwirkung von Mitteldestillaten
KR970038783U (ko) 분리재생이 가능케한 수도미터 케이스 뚜껑의 개량구조
SE9800424D0 (sv) Släckmedel i form av vatten med tillsatser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee